Grifols SA (GRFS) Quote

Gets a follow up M&A bid above 10.50 Euro?

Their stock sucks because they don't let anyone donate as They bruised both of my arms then after a week it healed then said I had a red spot on my left arm so I couldn't give in my right arm until the mosquito bite on my lef arm went away They're incompetence is disgusting in Colorado springs Colorado on pikes peak ave And took pictures of both arms and sent it to KKTV Call to action There's always lines waiting for CSL and BIOLIFE Plasma centers in Colorado springs and never a line at Grifols because they're incompetent I've had over 80 donations and had 20 straight completions before I went back to Grifols because they're way closer to my house and 15 completions before the miss this last time but they always trying to not get you to come back and hoping you go to the other companies And not many people go there in Colorado springs compared to the other companies I'm still trying to donate After a week and a half but getting ready to go back across town to a real company BioLife

GRFS under $10

GRFS under $10

Very likely which is why I took a starter. The company is on the right track from what I read,

Good morning Monroe. I believe this could double from here by years end.

I like this stock

Here's Why Grifols (GRFS) is Poised for a Turnaround After Losing -31.55% in 4 Weeks

https://finance.yahoo.com/news/heres-why-grifols-grfs-poised-143503975.html?.tsrc=rss

It's waay oversold btw.

"Grifols SA has an analyst consensus of Moderate Buy, with a price target consensus of $16.26, representing an 89.5% upside. In a report issued on January 4, Barclays also upgraded the stock to Buy with a EUR18.00 price target."

Chart concurs with those price targets by the way.

https://markets.businessinsider.com/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-nyxoah-nyxh-grifols-sa-grfs-1032962325

Plasma donations dropped drastically during the pandemic and is now recovering.
The plasma industry is a very lucrative business which pays the donors $30 - $50 for 880ml of plasma if not donated for free. That same 880ml bottle is then sold to biotechs for $1,000+ for R&D and manufacturing of pharmaceutical products. This company was founded in 1940 and is involved in all aspects of plasma - from donation centers to final products.

"The company's products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. Grifols, S.A. has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products, and with GIANT and GigaGen to develop recombinant polyclonal immunoglobulin therapies."

https://www.marketbeat.com/stocks/NASDAQ/GRFS/

Nice little bounce. I'll be watching this one.

Bullish day

GRFS buy 12.56

nice double bottom here if I might say so myself...

dipped toe today.

https://www.sec.gov/Archives/edgar/data/0001438569/000110465921048385/tm211749d1_20f.htm

"Young blood" research underway to turn back time in old people

https://sharylattkisson.com/2021/04/young-blood-research-underway-to-turn-back-time-in-old-people/?utm_source=ActiveCampaign&utm_medium=email&utm_content=Sharyl+Attkisson+Daily+Newsletter&utm_campaign=Daily+Newsletter

One large biotech firm, Grifols, is said to be responsible for at least six "phase 2" trials completed or underway to treat a wide range of age-related diseases, including Alzheimer's and Parkinson's, using blood or blood products extracted from youthful donors.

Nice 18 action to end the day/week.

Oldie but one of the reasons I’m here in and watching besides the machine sales in Wisconsin. That’s a bonus


https://www.alkahest.com/grifols-to-acquire-alkahest-to-enhance-discovery-research-and-development-to-identify-innovative-therapies-for-age-related-diseases-based-upon-an-understanding-of-the-human-plasma-proteome/

24,000 @ 17.50 in one shot pretty much. $420,000. Someone wants in.

Busy bugger this morning. Fun board. I can be the pumper & the basher, depending on my mood. Come on 18’s!

Dip and ........!

Come on 18’s!

Fun!

Ya but look at their recommendations SELL!

https://www.barchart.com/stocks/quotes/GRFS/technical-chart

Come on 17!!

Ha! I beat Credit Suisse to the punch. I’ve been getting discounted shares and today they found it. It’s the little joys in life. Cheers!

You like foreign stuff, try looking not RWLK then, out of Israel but also have US offices now, full FDA approvals in USA, Major Insurers behind them, Medicare/Medicaid coding also in place... Just not getting the right press from Business News outlets..

Someone sent this and bunch others to check out. It is an ADR from Bareclona, Spain. I vowed not to get involved with ADR's any longer. Last one was MTL out of Russia.. ADR fees eat you up if your stock just never moves...

anyne home???

Surprised that nobody is talking about GRFS right now.

They just collared with the FDA. International Pharmaceutical who specializes in fighting Infectious disease. Plasma clinical trials in Spain are showing tremendous success, and reps in the U.S. are being asked to get their PPE read to get ready for the same in America.

https://www.prnewswire.com/news-releases/grifols-announces-formal-collaboration-with-us-government-to-produce-the-first-treatment-specifically-targeting-covid-19-301029998.html

Solid news!

News: $GRFS Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies

BARCELONA, Spain , July 4, 2019 /PRNewswire/ -- Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ: GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify ® , its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (F...

Read the whole news Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies

I picked up a thousand on Friday. I totally agree.

This is a no brainer down here.

Loading.

Grifols Reports Solid 2014; No Fair Value Estimate Change as Fundamentals Remain StrongFont size: A | A | A
9:34 AM ET 2/26/15 | Morningstar
RELATED QUOTES


10:53 AM ET 2/26/15
Symbol Last % Chg
GRFS.ZY
34.12 0.71%
GRFS
34.14 0.78%
Real time quote.

Grifols reported strong results for 2014, with 22% top-line growth (24% at constant currencies) and a 32% adjusted EBITDA margin. This was slightly below our forecast on the top line, but profitability was stronger than we expected, putting bottom-line performance closer to our forecast. We're maintaining our EUR 34 per share ($39 per ADR) fair value estimate, and we remain confident in Grifols' narrow moat, which rests in its significant cost advantages in the global plasma market. While performance was boosted by the Novartis diagnostics acquisition in January, about 60% of Grifols' revenue is derived from North America, likely giving the firm a strong currency tailwind in 2015 and driving continued double-digit growth this year.
Grifols' plasma sales were weaker in 2014, which we believe is due to ex U.S. Factor VIII pressure and a more competitive U.S. hospital sales environment. The Bioscience division (now 75% of revenue) grew 2.6% in 2014 (4% at constant currencies). Performance has improved each quarter this year, but the 4.8% constant currency growth in the fourth quarter was well below the 8% growth in 2013. We think this is largely due to double-digit declines in sales of the firm's Factor VIII products in a very competitive environment, as recombinant products are increasingly used in emerging markets. However, Grifols noted that the U.S. plasma market was quite competitive in 2014 and that it did increase marketing and negotiate contracts (probably implying some pricing pressure, even in this higher-priced market). We think these comments apply to the immunoglobulin market, confirming recent comments from CSL, which pointed to pricing pressure for its fighting brand Carimune in price-sensitive hospital channels. However, we continue to view the top three global plasma firms as holding significant cost advantages over smaller players, and we think pricing power remains strong for premium brands, which are increasingly used chronically and at home.

Based on the U.S. To Euro valuation, the U.S. ADR should have closed at $34.5 today, which is what I was expecting.

Some MM ran it down today. I am ever hopeful that tomorrow's earnings release will meet and/or exceed estimates.


I'm telling everyone: This is the company that is poised for Alzheimer's treatment that works--plasma replacement. Replacing healthy plasma with plasma of diseased individuals is showing early promise.

Grifols should increase an easy 20% in the next few months.

http://www.fool.com/investing/general/2014/03/25/is-this-overlooked-stock-primed-for-more-growth.aspx

Check out this Foolish article.

http://seekingalpha.com/article/2517345-the-market-is-underestimating-the-potential-of-aradigms-lead-product-candidate


THIS IS HUGE! Grifols could explode northward soon! There is a reason Blackrock Advisors increased their stake. MHO

Black increases stake from 1.43% to 4.25%. WOW!

CEO Antonio Estabanell EDM
"We have used the falls to get more Grifols and Applus"
BEGOÑA BEARD ALBA MADRID 10.20.2014 7:33
Recommend on Facebook 2Tweet 8Send to LinkedIn 5

PRINT OUT
Related Topics:
EDM ManagementGrifolsGathered TechniquesIndraCatalana OccidenteMutual fundsFinancial marketsBusinessEconomyFinance

Estabanell Antonio, CEO of EDM.
MARTA YORDI
It is one of the oldest Spanish managers, with 25 years of life. Of Catalan origin, a specialist in Spanish and European equities and a pioneer in alternative investment. In late September administered 2,400 million.
Question. What are the main strengths of EDM?
Answer . Independence. Our sole aim is to offer good long-term results for our clients. As managers we have a selection based on individual assets in the portfolio, looking for companies that can grow, having good fundamental valuations but paying the right price style.
Q. After a week of vertigo in the stock market, do you think that falls mark a turnaround or are punctual?
R. 're in a very nervous market, which at the slightest wobble there are important corrections for psychological reasons we are nothing more than opportunities. We have seized falls to reinforce positions in securities with good long-term prospects, as Grifols, Applus, Essentra or Aggreko.
Q. How will behave markets?
R . We believe that given the situation in Europe, with such stagnant growth, monetary policy rates so low, rather than a country approach will be a large scatter in the prices of securities. We can have the stock of a country with shares having an excellent behavior with other nefarious behavior. The banking sector will behave similarly in different countries, since their results depend more on how the macroeconomic situation work.
Q. What are your favorite settings?
R . A value that is strongly Acerinox have bet, because it is a company that has done its homework. We like, as I said, Grifols, Catalana Occidente, Techniques Gathered and Indra. We believe that good deeds give good long-term results. We currently have more Spanish portfolio values ??at other times.
Q. And in Europe, what are your bets?
R . We weighted Roche. We see great opportunities in Capita Group, British company outsourcing and the German software giant SAP.
Q. In your opinion, how does the behavior of the bond?
R . The situation will be fixed very low yields for some time. The investor has to be aware of the environment in which we are, which are very low and even negative inflation. You have to look at real interest rates.
P. His connection to Catalonia, do you harm?
R . We do not position ourselves as a manager of Catalonia. We deposited vehicles in Ireland and Luxembourg. Our investment scope is global. The fact that our management team is in Barcelona is an anecdote.
Q. What changes in taxation?
R . We positively lowering of taxation on capital gains. Regarding income, we do not believe that there will be much decrease in taxation of the middle segments of the tax. Regarding Plan May expect their development. It does not seem very attractive need to be transformed into an annuity. We believe that increase individual pension funds.

EDM Management is present in Spain, Ireland, Luxembourg and the past year in Latin America funds sold through two American trading platforms, Pershing and DBH.
Q. Why have entered Latin America?
R. We felt that our expertise in security selection and management style was transferable to that geographical area initially but European values ??have launched a fund that invests in Latin American stocks. We manage 200 million euros there.
Q. What values ??provide more travel puddle jumping?
R . Dufry, a company of Swiss origin, but gives sales services in major Latin American airports. We also betting on the Brazilian bank Itaú and cosmetics firm Natura. And in Chile Falabella.
P. The political situation in Venezuela, Bolivia or Argentina, can affect the Spanish firms involved in the markets?
R. There are important uncertainties for companies operating in those countries. However, the consolidation of political systems can have very sustained growth in Peru, Colombia and Mexico.
P. Son of the pioneers in alternative investment, this business is dead?
R. With the financial crisis has changed much alternative investments. For private banks is probably dead because it is difficult to understand for the customer, but not for institutions. The volume of assets between institutional has increased and currently manage 80 million euros.

Ask yourself why are they so confident in a profit. Could it be data from Phase III looks positive>?

Dividend present by December. Wooohhooo!

https://www.yahoo.com/health/how-plasma-transfusions-from-survivors-fight-ebola-99999106587.html


Who is the plasma leader in the WORLD?

Grifols

The theory behind the transfusion treatment is this: The blood of an Ebola survivor should carry antibodies of the virus. By giving a current Ebola patient an injection of a compatible amount of blood plasma from someone who recovered from the disease, those antibodies could help the patient fight the virus.


http://www.washingtonpost.com/news/to-your-health/wp/2014/10/08/ebola-survivor-kent-brantly-donates-blood-to-help-treat-nbc-cameraman-ashoka-mukpo/

C'MON GRIFOLS!!!!!!!

Hello,

I am excited about the potential for Grifolis' Alzheimer's treatments.

I see this stock doubling in a year!